ReShape Lifesciences enters $9.7M at-the-market equity distribution agreement with Maxim Group

Vyome Holdings, Inc

Agreement allows sale of up to $9.7M of common stock via ATM offering; effective May 30, 2025.
Maxim receives 3.0% commission on gross proceeds plus up to $50K legal fee reimbursement and $3K per due diligence session.
Shares sold under existing effective S-3 shelf registration (File No. 333-287168).
Company has no obligation to sell; offering ends upon sale of $9.7M or termination by either party.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.